News Focus
News Focus
Followers 7
Posts 2799
Boards Moderated 0
Alias Born 01/17/2010

Re: Agent92260 post# 39319

Saturday, 10/02/2010 9:37:49 PM

Saturday, October 02, 2010 9:37:49 PM

Post# of 105535
sfraven, I am just analyzing the situation. Some heavy name bombs have been dropped around the CBAI.OB HQ operation. Osiris, Genzyme, Celgene, Perkin Elmer/Viacord, Blue Cross to name a few. BCBS has +20% ownership in Vita34. Why not CBAI? All valid questions when have a business connection with Blue. Maybe that all changes beginning next week. I will continue to monitor it.

Last institutional investor mentioned was May 09'. Cord Blood America Receives $2.3 Million For Stem Cell Lab
Matthew Schissler, founder and CEO of Cord Blood America, said: “The funding is from a private, institutional investor and allows us to focus even further on our due diligence efforts that I announced earlier. Certain properties of the funding will be recorded as both an asset and a liability on our books.” Asset-Liability is a Loan.
http://stemcellumbilicalcordblood.com/recent-news/cord-blood-america-recieves-23-million-for-stem-cell-lab/


Example of what I am looking for:
In June 2010, we sold seven million shares of our common stock to an institutional investor at a price of $0.865 per share. We received net proceeds, after deducting offering expenses and fees, of approximately $5,700,000. No warrants were issued in this transaction. The institutional investor has agreed to purchase an additional five million shares approximately 12 weeks after the initial purchase, at a price to be calculated using the then-current trading price, although we may elect not to sell the additional shares. No warrants would be issued in connection with the sale of the additional shares.
http://phx.corporate-ir.net/phoenix.zhtml?c=86230&p=irol-newsArticle_print&ID=1458561&highlight=

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today